Nivalis Therapeutics Company Profile (NASDAQ:NVLS)

About Nivalis Therapeutics

Nivalis Therapeutics logoNivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates through discovering and development of potential drugs segment. Its operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. Its product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVLS
  • CUSIP:
Key Metrics:
  • Previous Close: $6.48
  • 50 Day Moving Average: $7.81
  • 200 Day Moving Average: $5.56
  • 52-Week Range: $3.68 - $9.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.45
  • P/E Growth: 0.00
  • Market Cap: $100.46M
  • Outstanding Shares: 15,503,000
  • Beta: 0.14
  • Return on Equity: -36.45%
  • Return on Assets: -34.36%
  • Current Ratio: 12.64%
  • Quick Ratio: 12.64%
Additional Links:
Companies Related to Nivalis Therapeutics:

Analyst Ratings

Consensus Ratings for Nivalis Therapeutics (NASDAQ:NVLS) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.00 (177.78% upside)

Analysts' Ratings History for Nivalis Therapeutics (NASDAQ:NVLS)
DateFirmActionRatingPrice TargetDetails
9/13/2016Raymond James Financial Inc.Initiated CoverageOutperform$20.00View Rating Details
8/30/2016Piper Jaffray Cos.Reiterated RatingBuy$16.00View Rating Details
8/8/2016HC WainwrightReiterated RatingBuyView Rating Details
8/1/2016Cowen and CompanyReiterated RatingBuyView Rating Details
10/8/2015Robert W. BairdReiterated RatingPositive$29.00View Rating Details
7/13/2015Stifel NicolausInitiated CoverageBuyView Rating Details
(Data available from 10/26/2014 forward)


Earnings History for Nivalis Therapeutics (NASDAQ:NVLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2016Q2($0.52)($0.55)ViewN/AView Earnings Details
5/2/2016Q1 16($0.44)($0.51)ViewN/AView Earnings Details
2/29/2016Q4 15($0.36)($0.42)ViewN/AView Earnings Details
11/2/2015Q3 15($0.42)($0.39)ViewN/AView Earnings Details
4/18/2012$0.61$0.61ViewN/AView Earnings Details
2/2/2012$0.47$0.73ViewN/AView Earnings Details
10/26/2011$0.68$0.73ViewN/AView Earnings Details
7/11/2011$0.77$0.79ViewN/AView Earnings Details
4/27/2011$1.03$1.04ViewN/AView Earnings Details
1/31/2011$0.94$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Nivalis Therapeutics (NASDAQ:NVLS)
Current Year EPS Consensus Estimate: $-2.29 EPS
Next Year EPS Consensus Estimate: $-2.64 EPS


Dividend History for Nivalis Therapeutics (NASDAQ:NVLS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Nivalis Therapeutics (NASDAQ:NVLS)
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 83.12%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/4/2016David Malcom RodmanEVPSell5,820$7.96$46,327.20View SEC Filing  
7/5/2016David Malcom RodmanCMOSell5,950$4.66$27,727.00View SEC Filing  
6/16/2016Jon CongletonCEOBuy5,000$3.87$19,350.00View SEC Filing  
3/24/2016Jon CongletonCEOBuy5,000$4.22$21,100.00View SEC Filing  
3/22/2016Jon CongletonCEOBuy5,000$4.38$21,900.00View SEC Filing  
12/11/2015Jon CongletonCEOBuy5,000$8.10$40,500.00View SEC Filing  
12/9/2015Robert E ConwayDirectorBuy10,000$8.10$81,000.00View SEC Filing  
6/23/2015James E FlynnInsiderBuy250,000$14.00$3,500,000.00View SEC Filing  
6/22/2015Bay Master Investors (C HawkesMajor ShareholderBuy17,200$14.69$252,668.00View SEC Filing  
6/18/2015Bay Master Investors (C HawkesMajor ShareholderBuy20,400$14.47$295,188.00View SEC Filing  
6/17/2015Global Healthcare Mas JennisonMajor ShareholderBuy26,149$14.00$366,086.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Nivalis Therapeutics (NASDAQ:NVLS)
DateHeadline logoNivalis (NVLS) Reports Wider-than-Expected Loss in Q2 (NASDAQ:NVLS) - August 2 at 11:29 AM
News IconNivalis reports $8.5M loss in Q2, continues to work on drug to treat cystic fibrosis (NASDAQ:NVLS) - August 1 at 6:19 PM logoEARNINGS SUMMARY: Details of Nivalis Therapeutics, Inc. Q2 Earnings Report (NASDAQ:NVLS) - August 1 at 6:19 PM logoNivalis Therapeutics Reports Second Quarter 2016 Financial Results (NASDAQ:NVLS) - August 1 at 6:19 PM logoNivalis (NVLS): Can the Stock Surprise This Earnings Season? (NASDAQ:NVLS) - July 27 at 6:54 PM logoNivalis Therapeutics To Present At JMP Securities Conference; Webcast At 1:30PM (NASDAQ:NVLS) - July 14 at 10:06 AM
News IconNivalis Therapeutics files for $142.5M shelf registration (NASDAQ:NVLS) - July 8 at 9:30 AM logoNivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis (NASDAQ:NVLS) - July 7 at 7:11 AM logoNivalis Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:NVLS) - July 6 at 4:31 PM logoNivalis Therapeutics to Present at the JMP Securities Life Sciences Conference (NASDAQ:NVLS) - June 15 at 7:19 AM logoNivalis Therapeutics, Inc. :NVLS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 (NASDAQ:NVLS) - June 10 at 5:01 PM logoNivalis Therapeutics to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:NVLS) - June 1 at 7:23 AM logoNivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis (NASDAQ:NVLS) - May 16 at 4:22 PM logoEARNINGS SUMMARY: Details of Nivalis Therapeutics, Inc. Q1 Earnings Report (NASDAQ:NVLS) - May 3 at 2:48 PM logoNivalis Therapeutics reports 1Q loss (NASDAQ:NVLS) - May 2 at 5:27 PM logoNivalis Therapeutics Reports First Quarter 2016 Financial Results (NASDAQ:NVLS) - May 2 at 4:20 PM logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Sta (NASDAQ:NVLS) - April 22 at 4:32 PM logoNivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:NVLS) - April 22 at 4:16 PM logoNivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President of Discovery (NASDAQ:NVLS) - April 19 at 3:01 PM logoNivalis Therapeutics Names David Rodman As Chief Medical Officer (NASDAQ:NVLS) - April 18 at 8:22 AM
News IconRecently Changed Price Targets On Nivalis Therapeutics, Inc. (NVLS) (NASDAQ:NVLS) - April 9 at 2:36 PM logoThe U.S. Gets 2nd Biosimilar, ORMP Awaits Data This Qtr, PFE Hits Mark In OPAL (NASDAQ:NVLS) - April 6 at 2:47 PM logoNivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis (NASDAQ:NVLS) - April 5 at 8:20 AM logoNeed for Patient-Centric Clinical Trials Fuels Adoption of Greenphire's ClinCard Solution (NASDAQ:NVLS) - April 5 at 8:00 AM logoNIVALIS THERAPEUTICS, INC. Financials (NASDAQ:NVLS) - March 12 at 1:04 PM logoNIVALIS THERAPEUTICS, INC. Files SEC form 10-K, Annual Report (NASDAQ:NVLS) - March 8 at 5:03 PM logoNivalis (NVLS) Provides Update on Cystic Fibrosis Candidate (NASDAQ:NVLS) - March 8 at 4:00 PM logoNivalis Therapeutics (NVLS) Expands N91115 Clinical Development Program in CF (NASDAQ:NVLS) - March 8 at 1:37 PM logoNivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis (NASDAQ:NVLS) - March 7 at 4:05 PM logoNivalis Therapeutics to Present at Two Upcoming Investor Conferences (NASDAQ:NVLS) - March 2 at 8:00 AM logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (NASDAQ:NVLS) - March 1 at 5:48 PM logoNivalis Therapeutics Announces Appointment of Paul Sekhri to Its Board of Directors (NASDAQ:NVLS) - March 1 at 4:05 PM logoEARNINGS SUMMARY: Details of Nivalis Therapeutics, Inc. Q4 Earnings Report (NASDAQ:NVLS) - March 1 at 1:24 PM logoNivalis Therapeutics reports 4Q loss (NASDAQ:NVLS) - February 29 at 7:07 PM logoNivalis Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results (NASDAQ:NVLS) - February 29 at 4:05 PM logoNivalis Therapeutics, Inc. (NVLS) (NASDAQ:NVLS) - February 20 at 12:52 PM logoNivalis Therapeutics (NVLS) Granted FDA Fast Track Status for N91115 in CF (NASDAQ:NVLS) - February 19 at 1:20 PM logoApplied Materials, Nivalis & Nordstrom Lead Thursday's After-Hours Movers (NASDAQ:NVLS) - February 18 at 5:11 PM logoNivalis Therapeutics Announces FDA Fast Track Designation for N91115 in Patients With Cystic Fibrosis (NASDAQ:NVLS) - February 18 at 4:05 PM logoWhat Vertex’s Results Mean for Corbus, ProQR, and Nivalis (NASDAQ:NVLS) - February 16 at 11:36 AM logoWhat's in Store for Nivalis (NVLS) this Earnings Season? (NASDAQ:NVLS) - January 29 at 12:50 PM logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:NVLS) - January 26 at 5:02 PM logoNivalis' N91115 Gets Orphan Drug Status for Cystic Fibrosis (NASDAQ:NVLS) - January 18 at 2:55 PM logoNivalis CF drug gets FDA 'orphan drug' designation; stock rises Friday (NASDAQ:NVLS) - January 18 at 12:20 PM logoNivalis Therapeutics (NVLS) Jumps: Stock Moves Up 15.5% (NASDAQ:NVLS) - January 18 at 8:15 AM logoNivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis (NASDAQ:NVLS) - January 15 at 11:25 AM logo11:17 am Nivalis Therapeutics confirms being granted Orphan Designation by the FDA for N91115 in cystic fibrosis (NASDAQ:NVLS) - January 15 at 11:17 AM logoNIVALIS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:NVLS) - November 3 at 5:04 PM logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:NVLS) - November 2 at 5:03 PM logoNivalis Therapeutics Reports Third Quarter and Nine-Month Financial Results for 2015 (NASDAQ:NVLS) - November 2 at 4:26 PM


Nivalis Therapeutics (NASDAQ:NVLS) Chart for Wednesday, October, 26, 2016

Last Updated on 10/26/2016 by Staff